0000000000061064

AUTHOR

G. Valmadre

showing 2 related works from this author

PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyChemotherapyOncologybusiness.industrymedicine.medical_treatmentInternal medicinemedicinebusinessAdjuvantJournal of Thoracic Oncology
researchProduct

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E a…

2009

Background:Two parallel randomized phase 2 trialswere performed to choose the optimal way of combining cetuximab with gemcitabine in the first-line treatment of elderly (CALC1-E) and adult PS2 (CALC1-PS2) patients with advanced NSCLC. Methods: Stage IV or IIIB NSCLC patients, aged ≥70 years with PS 0–2 for CALC1-E or aged <70 with PS2 for CALC1-PS2, not selected for EGFR expression,were eligible. Patients were randomized to concomitant (gemcitabine, for a maximum of 6 cycles, plus cetuximab until progression) or sequential (gemcitabine, for a maximum of 6 cycles, followed by cetuximab) strategy. A selection design, with 1-year survival rate as the primary endpoint, was applied, requiring 58…

Pulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsAdolescentSettore MED/06 - Oncologia MedicaCetuximabNSCLCAntibodies Monoclonal HumanizedDeoxycytidinelaw.inventionYoung AdultRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerPS2 patientSurvival analysisAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryClinical trialTreatment OutcomeOncologyConcomitantPatient ComplianceFemalebusinessElderly patientmedicine.drug
researchProduct